Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HI-TECH 2
NCT07582835Phase 3Recruiting
- Sponsor
- Cardiocentro Ticino
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ticagrelor, prasugrel in coronary artery disease (CAD), acute coronary syndrome (ACS), sponsored by Cardiocentro Ticino. Started Apr 2026; status: recruiting.
02
Drugs
ticagrelorprasugrel
03
Conditions
coronary artery disease (CAD)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT07582835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07582835.